{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:10:57Z","timestamp":1772521857129,"version":"3.50.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Multiple myeloma (MM) is a genetically heterogeneous malignancy in which cytogenetic abnormalities, including gain or amplification of chromosome 1q (+1q), have been associated with adverse outcomes. We conducted a retrospective single-center study evaluating the impact of 1q alterations in MM patients treated with anti-CD38 monoclonal antibodies (daratumumab or isatuximab) between 2015 and 2024. Fluorescence\n                    <jats:italic>in situ<\/jats:italic>\n                    hybridization was performed to detect 1q gain or amplification and other high-risk cytogenetic abnormalities. A total of 149 patients were analyzed, with 115 receiving daratumumab and 34 isatuximab. In the daratumumab cohort, 51.3% harbored 1q alterations, with comparable baseline characteristics across groups. Patients with 1q alterations showed a lower rate of MRD negativity (20.3% vs 39.3%; p = 0.04) and a trend toward shorter PFS (26.3 vs 43.4 months; p = 0.05), while OS was similar overall (61.2 vs 68.7 months; p = 0.24), although 1q amplification was associated with poorer OS (42 vs 74 months; p = 0.029). These findings were not confirmed in multivariate analysis, where the line of anti-CD38 therapy emerged as the main variable significantly associated with both PFS and OS. In the isatuximab-treated group, 41% exhibited 1q alterations, with no significant differences in response rates, MRD negativity (28.6% vs 55%; p = 0.171), PFS (56.9 vs 58.2 months; p = 0.67), or OS (median not reached in either group; p = 0.27). The small sample size and low number of events precluded meaningful multivariate analysis. Overall, our findings suggest that 1q alterations are not independent prognostic factors in MM patients treated with anti-CD38 antibodies. The poorer outcomes observed in univariate analyses among daratumumab-treated patients with 1q alterations likely reflect a more advanced disease profile, including later lines of therapy and greater underlying disease risk, rather than the isolated effect of 1q alterations themselves. Comprehensive cytogenetic profiling and achieving MRD negativity remain critical for risk stratification and optimizing therapeutic strategies in MM patients receiving anti-CD38 therapies.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1758533","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:54Z","timestamp":1772520594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies"],"prefix":"10.3389","volume":"16","author":[{"given":"Mar\u00eda","family":"S\u00e1nchez-Tabernero","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]},{"name":"Faculty Of Medicine, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Zamanillo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Alonso-Fernandez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Fern\u00e1ndez-Guijarro","sequence":"additional","affiliation":[{"name":"Genetic Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Cortijo","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)","place":["Madrid, Spain"]},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC)","place":["Madrid, Spain"]},{"name":"Faculty Of Medicine, Universidad Complutense de Madrid","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.seminhematol.2024.10.001","article-title":"The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges","volume":"62","author":"Avigan","year":"2024","journal-title":"Semin Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2357382","article-title":"Anti-CD38 monoclonal antibodies in multiple myeloma with gain\/amplification of chromosome arm 1q: a review of the literature","volume":"24","author":"Barbieri","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hem3.70031","article-title":"High - risk cytogenetic abnormalities in multiple myeloma : PETHEMA - GEM experience Patient characteristics","volume":"8","author":"Calle","year":"2024","journal-title":"Hemasphere"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: The faster, the worse","volume":"129","author":"Wang","year":"2023","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European myeloma network (EMN) report within the HARMONY project","volume":"364","author":"D\u2019agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70127","article-title":"High - risk features of early relapse in newly - diagnosed multiple myeloma : The impact of cytogenetics and response to initial therapy","volume":"9","author":"Manubens","year":"2025","journal-title":"Hemasphere"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02506-1","article-title":"Daratumumab plus lenalidomide\/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study: MULTIPLE MYELOMA, GAMMOPATHIES","volume":"39","author":"Moreau","year":"2025","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma : A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2025","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS : an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:55Z","timestamp":1772520595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1758533"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1758533","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1758533"}}